Rockefeller Capital Management L.P. Has $103.02 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Rockefeller Capital Management L.P. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 98,004 shares of the biopharmaceutical company’s stock after selling 1,096 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Regeneron Pharmaceuticals were worth $103,021,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of REGN. Sachetta LLC raised its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $26,000. Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $33,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 0.2 %

Shares of Regeneron Pharmaceuticals stock opened at $754.87 on Friday. The company has a market capitalization of $82.95 billion, a P/E ratio of 18.68, a price-to-earnings-growth ratio of 2.91 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business has a 50-day moving average of $913.54 and a two-hundred day moving average of $1,020.69. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research analyst reports. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,107.29.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.